-5%
Roxagen is a first-in-class, oral HIF-PH inhibitor that helps stimulate erythropoiesis by increasing the body’s production of erythropoietin (EPO), improving iron regulation, and overcoming the EPO-suppressive effects of inflammation on hemoglobin production and red blood cell synthesis by reducing hepcidin.
Roxagen is prescribed for adult patients with symptomatic anemia associated with chronic kidney disease (CKD).
